BM-1197

• Product Name Alternative:

  UBX1967

• UNSPSC Description:

  BM-1197 (UBX1967) is a potent and selective inhibitor of dual Bcl-2/Bcl-xL, with IC50s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo[1][2].

• Target Antigen:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bm-1197.html

• Purity:

  99.48

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  C[S](=O)(C(C(C1=CC(N2CCN(C(C=C3)=CC=C3N[S](=O)(C(C=C4)=CC([S](C(F)(F)F)(=O)=O)=C4N[C@@H](CSC5=CC=CC=C5)CCN(CC6)CCC6O)=O)CC2)=CC(F)=C1)=C(C(C=C7)=CC=C7Cl)N8C(C)C)=C8C)=O

• Molecular Weight:

  1131.78

• References & Citations:

  [1]Bai L, et, al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014 Jun 5; 9(6): e99404.|[2]Sun YL, et, al. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer. 2019 Dec 31; 20(1):1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1391107-89-3